Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) Cell Therapy in Acute Myeloid Leukemia: A Systematic Review of the Literature.

Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells are attracting considerable interest as a potential therapeutic option in acute myeloid leukemia (AML), driven by the search for safe, scalable, and effective alternatives. To provide an overview of the current state of the field, a systematic review was performed to evaluate the safety and efficacy of CAR-NK cells for AML. The findings suggest possible directions for future development and also highlight important obstacles that must be addressed before they can be used in clinical settings. Therefore, although CAR-NK therapy remains in its early stages, its eventual application in AML is possible if these barriers can be resolved.